Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications

• US 6,607,501 B2
• Filed: 05/14/2001
• Issued: 08/19/2003
• Est. Priority Date: 05/14/2001
• Status: Expired due to Fees

• Current Assignee: Transvivo, Inc.
• Original Assignee: Reynolds G. Gorsuch, Transvivo, Inc.
• Inventors: Gorsuch, Reynolds G.
• Primary Examiner(s): Look, Edward K.
• Assistant Examiner(s): Fristoe, Jr., John K
• Application Number:
  US09/858,029
• Publication Number:
  US 20020188240A1
• Time in Patent Office: 827 Days
• Field of Search: 604/4.01, 604/5.01, 604/5.02, 604/5.03, 604/5.04, 604/6.01, 604/6.02, 604/6.03, 604/6.04, 604/6.05, 604/6.06, 604/6.07, 604/6.08, 604/6.09, 604/6.1, 604/6.11, 604/6.12, 604/6.13, 604/6.14, 604/6.65, 604/6.16, 604/7, 604/8, 604/9, 604/10
• US Class Current: 604/5.01
• CPC Class Codes: A61M 1/1678 intracorporal peritoneal dialysis A61M1/28
• CPC Class Codes: A61M 1/3489 by biological cells, e.g. bioreactor
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0415 Plasma
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention is directed to a method of treating cells, tissues or organs using in vivo plasma separation by implanting a plasma separation filter device within a blood vessel of a patient, or allogenic, or xenogenic donor, continuously separating blood plasma from whole blood in vivo, directing the plasma from the plasma separation filter device to a bioreactor, and exposing the plasma to cells, tissue or an organ within the bioreactor utilizing immune separation membranes where necessary.

Claims

1. A method of treating cells, tissues or organs comprising:

implanting an in vivo plasma separation device within a blood vessel of a patient or donor;

separating blood plasma from whole blood in vivo using said plasma separation device;

directing said plasma from the plasma separation device to a bioreactor; and

exposing said plasma to cells, tissue or organ in said bioreactor.

2. A method of claim 1 including directing the exposed plasma from said bioreactor to the patient or donor.

3. A method of claim 1 or 2 including monitoring levels of one or more dissolved gaseous components in said blood plasma between the patient or donor and said bioreactor.

4. A method of claim 3 including supplying one or more gases to said blood plasma in response to monitored gaseous component levels.

5. A method of claim 1 or 2 including directing the exposed plasma from the bioreactor to the capillary bed of a tissue structure or organ of the patient or donor.

6. A method of claim 1 or 2 including transplanting the treated cells, tissue or organ into the patient or donor.

7. A method of claim 6 wherein said plasma separation device comprises a plasmapheresis filter element secured on or adjacent to an end of a multiple lumen catheter having a first and a second lumen, said filter element comprising a hollow fiber and/or sheet membrane having a pore size capable of separating blood plasma and selected blood components from whole blood, passing said blood plasma and selected components through said membrane and directing said plasma and selected components through the first lumen of said catheter to said bioreactor.

8. A method of claim 1 or 2 comprising exposing a patient'"'"'s own cells, tissue or organ to autologous plasma in said bioreactor.

9. A method of claim 8 wherein said plasma separation device comprises a plasmapheresis filter element secured on or adjacent to an end of a multiple lumen catheter having a first and a second lumen, said filter element comprising a hollow fiber and/or sheet membrane having a pore size capable of separating blood plasma and selected blood components from whole blood, passing said blood plasma and selected components through said membrane and directing said plasma and selected components through the first lumen of said catheter to said bioreactor.

10. A method of claim 8 including transplanting the patient'"'"'s treated cells, tissue or organ into the patient.

11. A method of claim 10 including returning said exposed autologous plasma to the patient.

12. A method of claim 10 wherein said plasma separation device comprises a plasmapheresis filter element secured on or adjacent to an end of a multiple lumen catheter having a first and a second lumen, said filter element comprising a hollow fiber and/or sheet membrane having a pore size capable of separating blood plasma and selected blood components from whole blood, passing said blood plasma and selected components through said membrane and directing said plasma and selected components through the first lumen of said catheter to said bioreactor.

13. A method of claim 8 including returning said exposed autologous plasma to the patient.

14. A method of claim 1 or 2 comprising directing allogenic or xenogenic plasma from a donor to a bioreactor containing a patient'"'"'s cells, tissue or organ, passing the allogenic or xenogenic plasma through an immune isolation membrane and thereafter exposing the plasma to cells, tissue or organ, and directing the exposed plasma to a patient or donor.

15. A method of claim 14 including transplanting exposed cells, tissue or organ to a patient or donor.

16. A method of claim 14 wherein said plasma separation device comprises a plasmapheresis filter element secured on or adjacent to an end of a multiple lumen catheter having a first and a second lumen, said filter element comprising a hollow fiber and/or sheet membrane having a pore size capable of separating blood plasma and selected blood components from whole blood, passing said blood plasma and selected components through said membrane and directing said plasma and selected components through the first lumen of said catheter to said bioreactor.

17. A method of claim 1 or 2 wherein said plasma separation device comprises a plasmapheresis filter element secured on or adjacent to an end of a multiple lumen catheter having a first and a second lumen, said filter element comprising a hollow fiber and/or sheet membrane having a pore size capable of separating blood plasma and selected blood components from whole blood, passing said blood plasma and selected components through said hollow fiber and/or sheet membrane and directing said plasma and selected components through the first lumen of said catheter to said bioreactor.

18. A method of claim 17 including directing the exposed plasma from said bioreactor to a blood vessel of the patient or donor through the second lumen of said catheter.

19. A method of claim 17 including providing a cell culture bed in said bioreactor and passing said plasma through said cell culture bed, and exposing said plasma to substantially all cells in the cell culture bed.

20. A method of claim 17 including supplementing the plasma with one or more supplement compositions in said bioreactor.

21. A method of claim 17, treating the exposed plasma from the bioreactor to remove selected toxins or components thereof and thereafter directing the plasma to the patient or donor.

22. An apparatus for carrying out a method of treating cells, tissues or organs comprising:

a filter for being planted in a patient'"'"'s blood vessel comprising a plurality of elongated hollow microporous fibers having an interior lumen and a fiber wall having a pore size capable of allowing plasma to diffuse therethrough, wherein said fibers comprise a fiber wall having a plurality of zones between the inner and outer wall surfaces, each of said zones having a mass density different than the mass density of an adjacent zone, said fiber wall characterized by having a lower mass density zone at the inner wall surface and a higher mass density zone at the outer wall surface;

a multiple lumen catheter in fluid communication with the interior fiber lumen including a first lumen for directing separated blood plasma from said fiber lumen and a second lumen for directing blood plasma to the patient;

a bioreactor; and

a first conduit for directing plasma from the first lumen to said bioreactor, and a second conduit for directing exposed plasma from said bioreactor to the second lumen.

23. An apparatus of claim 22 wherein said membrane fiber wall has two mass density zones.

24. An apparatus of claim 22 wherein said membrane fiber wall has three mass density zones.

25. An apparatus of claim 22 wherein membrane fiber wall has four or more mass density zones.

26. An apparatus of claim 23, 24 or 25 wherein each of said zones is characterized by a different average nominal pore size.

27. An apparatus of claim 26 wherein the fiber wall structure comprises a continuous change in mass density from the outer wall surface to the inner wall surface.

28. An apparatus of claim 26 wherein said lower mass density zone is characterized by a nominal average pore diameter of between about 1 μ

m and about 60 μ

m.

29. An apparatus of claim 28 wherein said higher mass density zone is characterized by a nominal average pore diameter of between about 0.3 μ

m and about 1 μ

m.

30. An apparatus of claim 26 wherein said higher mass density zone is characterized by a nominal average pore diameter of between about 0.3 μ

m and about 1 μ

m.

31. An apparatus of claim 22 characterized by having the capability of extracting at least 0.75 (ml/min)(cm²×

mm Hg) of blood plasma at trans-membrane pressures of between about 5 and about 20 mm Hg.

32. An apparatus of claim 22 wherein the fiber wall structure comprises a continuous change in mass density from the outer wall surface to the inner wall surface.